title: Effect of Sanqi Oral Liquid on the expressions of CD4⁺, CD8⁺ and CD68⁺ cells in 5/6 nephrectomized rats with chronic renal failure.
abstract: OBJECTIVE
  To explore the mechanisms of Chinese herbal medicine Sanqi Oral Liquid, composed of Astragalus membranaceus and Panpax notoginseng, in alleviating renal injury by observing its effect on the expressions of CD4(+), CD8(+) and CD68(+) cells in 5/6 nephrectomized rats with chronic renal failure.
  
  
  METHODS
  A total of 102 SD rats were randomly divided into six groups: three treatment groups were administrated with high, medium and low dosage of Sanqi Oral Liquid respectively by gavage; a normal group, a 5/6 nephrectomized model group, and a group treated with coated aldehyde oxygenstarch were used as controls. Following oral administration of Sanqi Oral Liquid for 12 weeks, the general condition and renal pathological changes were observed, and the renal function, platelet count (PLT) and the expressions of CD4(+), CD8(+) and CD68(+) cells were determined for each group.
  
  
  RESULTS
  There were proliferation of mesangial matrix, renaltubularnecrosis and obvious tubulointerstitial fibrosis in the model group, and they were much milder in the treatment groups. Compared with the model group, the amounts of blood urea nitrogen (BUN), serum creatinine (Scr) and PLT in the treatment groups decreased (P<0.05 for all); and in the group administrated of medium dosage of Sanqi Oral Liquid, the expression of CD4(+) cells was up-regulated and those of CD8(+) and CD68(+) cells were down-regulated (P<0.05 for all), leading to an increased ratio of CD4(+)/CD8(+)(P<0.01).
  
  
  CONCLUSIONS
  Sanqi Oral Liquid has a significant effect on regulating lymphocyte subsets, reducing the infiltration of macrophages in renal tissues and alleviating tubulointerstitial fibrosis, and this may be one of mechanisms of Sanqi Oral Liquid in delaying the progression of chronic kidney diseases.
authors.affiliation: Department of Urology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
authors.forename: Fang-Ning
authors.initials: FN
authors.lastname: Wei
authors.forename: Zi-Lin
authors.initials: ZL
authors.lastname: Chen
authors.forename: Hai-Feng
authors.initials: HF
authors.lastname: Yang
authors.forename: Ling
authors.initials: L
authors.lastname: Han
authors.forename: Hai-Ming
authors.initials: HM
authors.lastname: Ding
authors.forename: Shi-Gui
authors.initials: SG
authors.lastname: Deng
authors.forename: Run-Mei
authors.initials: RM
authors.lastname: Ou
authors.forename: Ai-Hua
authors.initials: AH
authors.lastname: Ou
authors.forename: Yan-Fen
authors.initials: YF
authors.lastname: Liang
authors.forename: Zi-Heng
authors.initials: ZH
authors.lastname: Hu
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Yang
authors.forename: Ni-Zhi
authors.initials: NZ
authors.lastname: Yang
mesh_terms: D000284:Administration, Oral; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D027885:Astragalus propinquus / Q000737:chemistry; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D004353:Drug Evaluation, Preclinical; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D018655:Lymphocyte Count; D008297:Male; D009392:Nephrectomy; D053723:Panax notoginseng / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D012996:Solutions; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D004365:Drugs, Chinese Herbal; D012996:Solutions; C539355:CD68 protein, rat; D000097382:CD68 Molecule; C587496:sanqi